[In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori].
OBJECTIVE
To investigate the antimicrobial activity of Pariet, Tekpron, Nexium, respectively, against Helicobacter pylori (H. pylori) in vitro.


METHODS
Antimicrobial effects of these medicines were evaluated through detection of MICs for 3 H. pylori strains isolated from different countries.


RESULTS
The MIC(99) contents were 2.25 mg/L, 42.5 mg/L and 360 mg/L, respectively, for the three medicines. The strains under testing exhibited the same susceptibility to each medicine. Nexium did not inhibit the bacteria under the concentration of 3.6 - 36 mg/L with more and bigger H. pylori colonies seen when compared with controls.


CONCLUSIONS
The growth inhibitory activity appeared to be different among the three PPI medicines under investigation, with Rabeprazole the most potential agent of the three. Data suggested that the action of growth inhibition in vitro was resting on the characteristic of the given PPI as well as the supplements of the medicine.
He
Li-hua
LH
Department of Diagnosis, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Preventive, Beijing 102206, China.
Yin
Yan
Y
You
Yuan-hai
YH
Yan
Xiao-mei
XM
Zhang
Jian-zhong
JZ
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D064098:Esomeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016480:Helicobacter pylori / Q000187:drug effects*; D064747:Lansoprazole; D008826:Microbial Sensitivity Tests; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D064098:Esomeprazole